OBX
NASDAQ HealthcareObsidian Therapeutics, Inc. - Common Stock
Biotechnology
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $17.75 |
|---|---|
| 成交量 | 3,974,349 |
| 市值 | 1.10B |
| 贝塔系数 | 2.600 |
| RSI（14日） | 57.4 |
| 52周最高 | $49.97 |
| 52周最低 | $14.57 |
| Forward P/E | -8.33 |
| Price / Book | -1.36 |
🎯 投资策略评分
OBX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (94/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 OBX in your text
粘贴任何文章、记录或帖子 — 工具将提取 OBX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-18.